Elizabeth L Dickson1, Rachel Isaksson Vogel2, Paola A Gehrig3, Stuart Pierce3, Laura Havrilesky4, Angeles Alvarez Secord4, Joseph Dottino4, Amanda N Fader5, Stephanie Ricci5, Melissa A Geller6. 1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Minnesota, United States. 2. Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, United States. 3. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, United States. 4. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University, United States. 5. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Hospital, United States. 6. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Minnesota, United States. Electronic address: gelle005@umn.edu.
Abstract
OBJECTIVE: To evaluate the use of adjuvant therapy after primary surgery for stage I-III uterine carcinosarcoma (CS). METHODS: A multi-institutional retrospective study of women with stage I-III CS was conducted. Analyses were stratified by stage (I/II and III). Patients were categorized according to adjuvant therapy: observation (OBS), radiation (RT), chemotherapy (CT) or multimodal therapy (CT+RT). Overall survival (OS) and progression-free survival (PFS) were analyzed using log-rank tests and Cox proportional hazards models. RESULTS: 303 patients were identified across four institutions: 195 with stage I/II and 108 with stage III disease. In stage I/II disease, 75 (39.9%) received OBS, 33 (17.6%) CT, 37 (19.7%) RT, and 43 (22.9%) CT+RT. OBS was associated with a fourfold increased risk of death compared to CT (adjusted hazard ratio (aHR)=4.48, p=0.003). Patients receiving CT+RT had significantly improved PFS compared to those receiving CT alone (aHR=0.43, p=0.04), but no difference in OS. In the stage III cohort, 16 (15.0%) received OBS, 34 (31.8%) CT, 20 (18.7%) RT, and 37 (34.6%) CT+RT. OBS was associated with worse OS and PFS compared to CT (OS: aHR=2.46, p=0.04; PFS: aHR=2.39, p=0.03, respectively). A potential improvement in PFS was seen for those treated with CT+RT compared to CT alone, however it was not statistically significant (aHR=0.53, p=0.09). CONCLUSIONS: Observation after surgery was associated with poor outcomes in uterine CS compared to CT and RT alone. Multimodality therapy for women with stage I/II disease was associated with improved PFS compared to chemotherapy alone. Novel treatment options are needed to improve outcomes in this aggressive disease.
OBJECTIVE: To evaluate the use of adjuvant therapy after primary surgery for stage I-III uterine carcinosarcoma (CS). METHODS: A multi-institutional retrospective study of women with stage I-III CS was conducted. Analyses were stratified by stage (I/II and III). Patients were categorized according to adjuvant therapy: observation (OBS), radiation (RT), chemotherapy (CT) or multimodal therapy (CT+RT). Overall survival (OS) and progression-free survival (PFS) were analyzed using log-rank tests and Cox proportional hazards models. RESULTS: 303 patients were identified across four institutions: 195 with stage I/II and 108 with stage III disease. In stage I/II disease, 75 (39.9%) received OBS, 33 (17.6%) CT, 37 (19.7%) RT, and 43 (22.9%) CT+RT. OBS was associated with a fourfold increased risk of death compared to CT (adjusted hazard ratio (aHR)=4.48, p=0.003). Patients receiving CT+RT had significantly improved PFS compared to those receiving CT alone (aHR=0.43, p=0.04), but no difference in OS. In the stage III cohort, 16 (15.0%) received OBS, 34 (31.8%) CT, 20 (18.7%) RT, and 37 (34.6%) CT+RT. OBS was associated with worse OS and PFS compared to CT (OS: aHR=2.46, p=0.04; PFS: aHR=2.39, p=0.03, respectively). A potential improvement in PFS was seen for those treated with CT+RT compared to CT alone, however it was not statistically significant (aHR=0.53, p=0.09). CONCLUSIONS: Observation after surgery was associated with poor outcomes in uterine CS compared to CT and RT alone. Multimodality therapy for women with stage I/II disease was associated with improved PFS compared to chemotherapy alone. Novel treatment options are needed to improve outcomes in this aggressive disease.
Authors: Leigh A Cantrell; Laura Havrilesky; Dominic T Moore; David O'Malley; Margaret Liotta; Angeles Alvarez Secord; Christa I Nagel; David E Cohn; Amanda Nickles Fader; Amy H Wallace; Peter Rose; Paola A Gehrig Journal: Gynecol Oncol Date: 2012-06-20 Impact factor: 5.482
Authors: Mark H Einstein; Merieme Klobocista; June Y Hou; Stephen Lee; Subhakar Mutyala; Keyur Mehta; Laura L Reimers; Dennis Y-S Kuo; Gloria S Huang; Gary L Goldberg Journal: Gynecol Oncol Date: 2011-11-03 Impact factor: 5.482
Authors: Frederic Amant; Isabelle Cadron; Luca Fuso; Patrick Berteloot; Eric de Jonge; Gerd Jacomen; Johan Van Robaeys; Patrick Neven; Philippe Moerman; Ignace Vergote Journal: Gynecol Oncol Date: 2005-08 Impact factor: 5.482
Authors: Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe Journal: Gynecol Oncol Date: 2007-09-05 Impact factor: 5.482
Authors: F J Major; J A Blessing; S G Silverberg; C P Morrow; W T Creasman; J L Currie; E Yordan; M F Brady Journal: Cancer Date: 1993-02-15 Impact factor: 6.860
Authors: Jesus Gonzalez Bosquet; Shelby A Terstriep; William A Cliby; Monica Brown-Jones; Judith S Kaur; Karl C Podratz; Gary L Keeney Journal: Gynecol Oncol Date: 2009-11-05 Impact factor: 5.304
Authors: Katherine C Kurnit; Rebecca A Previs; Pamela T Soliman; Shannon N Westin; Ann H Klopp; Bryan M Fellman; Karen H Lu; Lois M Ramondetta; Nicole D Fleming Journal: Gynecol Oncol Date: 2018-11-08 Impact factor: 5.482
Authors: Kathryn A Mills; Heather Lopez; Lulu Sun; James C Cripe; Taylor Litz; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh Journal: Gynecol Oncol Rep Date: 2019-05-23
Authors: Kerri Beckmann; Sudarshan Selva-Nayagam; Ian Olver; Caroline Miller; Elizabeth S Buckley; Kate Powell; Dianne Buranyi-Trevarton; Raghu Gowda; David Roder; Martin K Oehler Journal: Cancer Manag Res Date: 2021-06-10 Impact factor: 3.989
Authors: Lori Cory; Colleen Brensinger; Robert A Burger; Robert L Giuntoli; Mark A Morgan; Nawar Latif; Lilie L Lin; Emily M Ko Journal: Gynecol Oncol Rep Date: 2022-01-17